GO Main Menu Go Main Contents Go Bottom Menu

CelltrionHealthcare

gnb show

MENU

Gnb close

Overview

The total export value of Remsima image

780million(EUR)
The total export value of Remsima®
In October 2016, Remsima®'s total export value reached EUR 780 million (the Korea International Trade Association).

Number of overseas subsidiaries image

32countries
Number of overseas subsidiaries
The number of countries with Celltrion Healthcare’s overseas subsidiaries(2019).

Number of global partners image

38partners
Number of global partners
Global partners in charge of the biologics’ distribution along with Celltrion Healthcare(2019).

Remsima's market share bypassing that of the orginator image

52%
Remsima®'s market share
bypassing that of the orginator
Remsima® is the first mAb biosimilar to bypass the originator's market share in Europe (2017).

Sales market image

110countries
Sales market
The number of countries where Celltrion Healthcare’s core biosimilars are available for purchase(and officially approved, 2019).

The total value of Remsima prescribed in the world image

770million(EUR)
The annual value of Remsima®
prescribed in the world
For the first time as a Korean medication,
the annual value of Remsima® prescribed across the world reached EUR 770million (2018).

Cookie technology helps us bring you the best possible experience when you visit this website. If you continue without changing your settings, you are agreeing to the cookies on this website. To learn more about our policy on cookies, please review our privacy policy via the link at the bottom of the page.